BAISHIDENG PUBLISHING GROUP INC
8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242 Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology
ESPS manuscript NO: 20981
Title: Targeting Enhancer of Zeste Homolog 2 as a promising strategy for cancer treatment
Reviewer's code: 00573188
Reviewer's country: Spain
Science editor: Xue-Mei Gong
Date sent for review: 2015-06-30 09:51
Date reviewed: 2015-08-27 22:04

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
[ ] Grade A: Excellent	[ ] Grade A: Priority publishing	Google Search:	[ ] Accept
[ ] Grade B: Very good	[Y] Grade B: Minor language polishing	[ ] The same title	[ ] High priority for publication
[Y] Grade C: Good	[ ] Grade C: A great deal of language polishing	[ ] Duplicate publication	[ ] Rejection
[ ] Grade D: Fair	[ ] Grade D: Rejected	[ ] Plagiarism	[Y] Minor revision
[ ] Grade E: Poor		[Y] No	[ ] Major revision
		BPG Search:	
		[ ] The same title	
		[ ] Duplicate publication	
		[ ] Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

Please, see attached file.

BAISHIDENG PUBLISHING GROUP INC
8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242 Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology
ESPS manuscript NO: 20981
Title: Targeting Enhancer of Zeste Homolog 2 as a promising strategy for cancer treatment
Reviewer's code: 00066723
Reviewer's country: Netherlands
Science editor: Xue-Mei Gong
Date sent for review: 2015-06-30 09:51
Date reviewed: 2015-09-03 22:49

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
[ ] Grade A: Excellent	[ ] Grade A: Priority publishing	Google Search:	[ ] Accept
[ ] Grade B: Very good	[Y] Grade B: Minor language polishing	[ ] The same title	[ ] High priority for publication
[Y] Grade C: Good	[ ] Grade C: A great deal of language polishing	[ ] Duplicate publication	[ ] Rejection
[ ] Grade D: Fair	[ ] Grade D: Rejected	[ ] Plagiarism	[Y] Minor revision
[ ] Grade E: Poor		[Y] No	[ ] Major revision
		BPG Search:	
		[ ] The same title	
		[ ] Duplicate publication	
		[ ] Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

The manuscript deals with the role of EZH2 in biology and disease with special emphasis on EZH2 as therapeutic target in cancer. The review is a comprehensive overview of the literature but lacks a critical note and directions. The reader needs some guidance how to interpret (and judge on its merits) the considerable amount of literature on the topic. The final chapter (conclusions) should clearly list the most promising developments and future perspectives without going in too much detail. Question of interest are: Are there still questions that need to answered regarding EZH2 and the PRC2 complex? How well defined is EZH2 ' role in cancer? Is it sensible to target such an important molecule that fulfills crucial roles in development? What kind of adverse effects can be expected? Major comments 1. Carefully check English grammar throughout the manuscript 2. It is informative to more elaborately discuss the composition of the PRC2 complex after all this is the context in which EZH2 operates. 3. Page 12, line 1-2 – One cannot say that the miRNAs listed here let7a-d, miR-26a, miR-101, miR-146a, miR-200b,c are tumor-suppressive miRNAs this totally depends on cancer type and context. Minor comments 1. Please number the pages this is really convenient

for the reviewer. 2. Abstract, line 12 – Note that the manuscript is a review not a commentary. 3. Abstract, line 16 – "Moreover, mutations of these proteins…." What do the authors mean? Which proteins are meant in this sentence? Please clarify. 4. Page 7, line 4 – 7 – "Furthermore, the recruitment…….tissue specific differences of EZH2 activity." It is unclear what the authors try to convey here. Please rephrase. 5. Page 8, line 1-2 – One reads "…., in fact several studies reported that it is also able to methylate other proteins" Unfortunately references are missing. 6. Page 15, line 8-9 – "…resistance of cancer cells often associated to the treatment with the only chemotherapeutic agents". What is meant here? Please rephrase.

BAISHIDENG PUBLISHING GROUP INC
8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242 Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology
ESPS manuscript NO: 20981
Title: Targeting Enhancer of Zeste Homolog 2 as a promising strategy for cancer treatment
Reviewer's code: 00504183
Reviewer's country: United States
Science editor: Xue-Mei Gong
Date sent for review: 2015-06-30 09:51
Date reviewed: 2015-08-17 01:52

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
[ ] Grade A: Excellent	[Y] Grade A: Priority publishing	Google Search:	[ ] Accept
[Y] Grade B: Very good	[ ] Grade B: Minor language polishing	[ ] The same title	[ ] High priority for publication
[ ] Grade C: Good	[ ] Grade C: A great deal of language polishing	[ ] Duplicate publication	[ ] Rejection
[ ] Grade D: Fair	[ ] Grade D: Rejected	[ ] Plagiarism	[Y] Minor revision
[ ] Grade E: Poor		[Y] No	[ ] Major revision
		BPG Search:	
		[ ] The same title	
		[ ] Duplicate publication	
		[ ] Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

This is a very interesting and well-written commentary on the molecular role of EZH2 and potential clinical implications for therapeutic targeting in cancer. A minor comment is that the manuscript would benefit of a comprehensive table listing all the different targettng strategies and the corresponding level of development (in vitro, phase 1, 2 etc) as well as a small separate description of the most important results of these studies.